RxDoctor Payments Data

Adam Blakeman, PA

Medical · Rigby, IDNPI 1275071128

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 25.7% of the total. Among medical clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,563in general payments, 2019–2025

Across 220 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$915
  • Axsome Therapeutics, Inc.$305
  • Lilly USA, LLC$237
  • Astellas Pharma US Inc$234
  • AstraZeneca$172
  • Otsuka America Pharmaceutical, Inc.$140
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,563 in reported general payments places this provider in the 90th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$56,694
Medicare patients
256
Services billed
1,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$35,390
EliquisApixaban31$26,319
OzempicSemaglutide23$20,905
FarxigaDapagliflozin Propanediol21$15,108
Xigduo XrDapaglifloz Propaned/Metformin16$10,748
TrintellixVortioxetine Hydrobromide14$8,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,172
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$8,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,085
Celecoxib66$5,993
Spiriva HandihalerTiotropium Bromide12$5,886
Pregabalin73$4,965
Aripiprazole20$2,219
Levothyroxine Sodium201$2,098
Ondansetron OdtOndansetron30$1,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$237$35,39034 claims
PfizerEliquis$127$26,31931 claims
Novo NordiskOzempic$73$20,90523 claims
AstraZenecaFarxiga$172$15,10821 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$51$8,58314 claims
GSKTrelegy Ellipta$121$8,17213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 medical providers in Idaho.

Other medical in Rigby

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →